GlassScriptPhysician profile
Michael S Rosen
NPI 1619931672
$20,141.20
in general payments reported to CMS, 2019-2025
42 companies · $3,325 in 2025
The $3,325 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,264 · 2020: $2,031 · 2021: $2,138 · 2022: $3,012 · 2023: $3,722 · 2024: $3,650 · 2025: $3,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,616.98 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,384.99 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Abbvie INC. | $1,890.02 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,312.14 | 2019-2025 | |
| Janssen Biotech, INC. | $1,280.46 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $1,230.43 | 2019-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $1,160.45 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $1,091.63 | 2020-2025 | Orencia |
| Pfizer INC. | $1,009.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $624.46 | 2019-2025 | Benlysta |
| Radius Health, INC. | $547.40 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $504.05 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $465.93 | 2021-2025 | Acthar |
| Genentech USA, INC. | $396.45 | 2019-2025 | Actemra |
| Lilly USA, LLC | $336.20 | 2019-2025 | Taltz, Olumiant |
| Organon LLC | $262.14 | 2023-2025 | Renflexis, Hadlima |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $259.98 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $220.85 | 2021-2025 | Lupkynis |
| Depuy Synthes Sales INC. | $204.28 | 2019-2025 | Monovisc, Orthovisc |
| Janssen Scientific Affairs, LLC | $189.04 | 2020-2024 | Tremfya |
| Fresenius Kabi USA, LLC | $186.40 | 2023-2025 | Idacio, Adalimumab-Aacf, Tyenne |
| Alexion Pharmaceuticals, INC. | $176.25 | 2019-2024 | Ultomiris |
| Medexus Pharma, INC. | $168.46 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.46 | 2019-2024 | Cyltezo |
| Sandoz INC. | $137.41 | 2023-2025 | Hyrimoz, Jubbonti |
| Kiniksa Pharmaceuticals International, Plc | $133.37 | 2024 | Arcalyst |
| Sobi, INC | $111.57 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $85.14 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Celgene Corporation | $82.48 | 2019 | |
| Ani Pharmaceuticals, INC. | $71.84 | 2023-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $60.77 | 2024-2025 | Hyqvia |
| Kyowa Kirin, INC. | $54.61 | 2023-2025 | Crysvita |
| Tonix Medicines, INC. | $45.69 | 2025 | Tonmya |
| Merck Sharp & Dohme LLC | $45.36 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $44.77 | 2022-2023 | Euflexxa |
| Ultragenyx Pharmaceutical INC. | $42.36 | 2019-2021 | |
| Mylan Institutional INC. | $36.90 | 2023 | Hulio, Fulphila |
| Pacira Therapeutics, INC. | $29.31 | 2019 | |
| Bioventus LLC | $27.99 | 2022 | |
| Invivyd INC | $27.51 | 2025 | Pemgarda |
| Fidia Pharma USA INC. | $24.94 | 2024 | Hymovis |
| Oxford Immunotec USA INC | $23.19 | 2021 | |
| Shire North American Group INC | $16.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.